Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)

Autor: Amari, Lyria, Tomasini, Pascale, Dantony, Emmanuelle, Rousseau-Bussac, Gaelle, Ricordel, Charles, Bigay-Game, Laurence, Arpin, Dominique, Morel, Hugues, Veillon, Remi, Justeau, Grégoire, Huchot, Eric, Fournel, Pierre, Vergnenegre, Alain, Bizeux, Acya, Subtil, Fabien, Clarisse, Bénédicte, Decroisette, Chantal, Chouaid, Christos, Greillier, Laurent, Bylicki, Olivier
Zdroj: In Lung Cancer July 2024 193
Databáze: ScienceDirect
Externí odkaz: